Difference between revisions of "Cloxacillin"

(general drug info)
(adult dosing)
Line 5: Line 5:
  
 
==Adult Dosing==
 
==Adult Dosing==
 +
===Upper Respiratory Tract Infection===
 +
* 250 mg PO q6hrs for 7-14 days
 +
 +
===Pneumonia===
 +
* 500 mg PO q6hrs for up to 21 days
 +
 +
===Soft tissue/skin infection===
 +
*500 mg PO q6hrs for 7 days or until 3 days after acute inflammation resolves
  
 
==Pediatric Dosing==
 
==Pediatric Dosing==

Revision as of 02:06, 7 February 2016

General

  • Type: Beta lactamase resistant penicillins
  • Dosage Forms: 125 mg/5 ml oral powder, 250 mg, 500 mg
  • Common Trade Names: Cloxapen, Dry Clox, Tegopen

Adult Dosing

Upper Respiratory Tract Infection

  • 250 mg PO q6hrs for 7-14 days

Pneumonia

  • 500 mg PO q6hrs for up to 21 days

Soft tissue/skin infection

  • 500 mg PO q6hrs for 7 days or until 3 days after acute inflammation resolves

Pediatric Dosing

Special Populations

  • Pregnancy Rating:
  • Lactation:
  • Renal Dosing
    • Adult
    • Pediatric
  • Hepatic Dosing
    • Adult
    • Pediatric

Contraindications

  • Allergy to class/drug

Adverse Reactions

Serious

Common

Pharmacology

  • Half-life:
  • Metabolism:
  • Excretion:
  • Mechanism of Action:

Antibiotic Sensitivities[1]

Group Organism Sensitivity
Gram Positive Strep. Group A, B, C, G S
Strep. Pneumoniae S
Viridans strep I
Strep. anginosus gp S
Enterococcus faecalis R
Enterococcus faecium R
MSSA S
MRSA R
CA-MRSA R
Staph. Epidermidis S
C. jeikeium R
L. monocytogenes R
Gram Negatives N. gonorrhoeae R
N. meningitidis R
Moraxella catarrhalis R
H. influenzae R
E. coli R
Klebsiella sp R
E. coli/Klebsiella ESBL+ R
E coli/Klebsiella KPC+ R
Enterobacter sp, AmpC neg R
Enterobacter sp, AmpC pos R
Serratia sp R
Serratia marcescens X1
Salmonella sp R
Shigella sp R
Proteus mirabilis R
Proteus vulgaris R
Providencia sp. R
Morganella sp. R
Citrobacter freundii R
Citrobacter diversus R
Citrobacter sp. R
Aeromonas sp R
Acinetobacter sp. R
Pseudomonas aeruginosa R
Burkholderia cepacia R
Stenotrophomonas maltophilia R
Yersinia enterocolitica R
Francisella tularensis X1
Brucella sp. X1
Legionella sp. R
Pasteurella multocida R
Haemophilus ducreyi X1
Vibrio vulnificus X1
Misc Chlamydophila sp R
Mycoplasm pneumoniae R
Rickettsia sp X1
Mycobacterium avium X1
Anaerobes Actinomyces R
Bacteroides fragilis R
Prevotella melaninogenica R
Clostridium difficile X1
Clostridium (not difficile) X1
Fusobacterium necrophorum X1
Peptostreptococcus sp. S

Key

  • S susceptible/sensitive (usually)
  • I intermediate (variably susceptible/resistant)
  • R resistant (or not effective clinically)
  • S+ synergistic with cell wall antibiotics
  • U sensitive for UTI only (non systemic infection)
  • X1 no data
  • X2 active in vitro, but not used clinically
  • X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
  • X4 active in vitro, but not clinically effective for strep pneumonia

See Also

Source

  1. Sanford Guide to Antimicrobial Therapy 2014